JP5859557B2 - 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 - Google Patents

補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 Download PDF

Info

Publication number
JP5859557B2
JP5859557B2 JP2013537784A JP2013537784A JP5859557B2 JP 5859557 B2 JP5859557 B2 JP 5859557B2 JP 2013537784 A JP2013537784 A JP 2013537784A JP 2013537784 A JP2013537784 A JP 2013537784A JP 5859557 B2 JP5859557 B2 JP 5859557B2
Authority
JP
Japan
Prior art keywords
ic3b
lateral flow
flow immunoassay
complement
intact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013537784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502347A5 (enExample
JP2014502347A (ja
Inventor
ポール オルソン,
ポール オルソン,
ドナルド モス,
ドナルド モス,
Original Assignee
カイファ, インコーポレイテッド
カイファ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイファ, インコーポレイテッド, カイファ, インコーポレイテッド filed Critical カイファ, インコーポレイテッド
Publication of JP2014502347A publication Critical patent/JP2014502347A/ja
Publication of JP2014502347A5 publication Critical patent/JP2014502347A5/ja
Application granted granted Critical
Publication of JP5859557B2 publication Critical patent/JP5859557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
JP2013537784A 2010-11-02 2011-11-02 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法 Active JP5859557B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40929710P 2010-11-02 2010-11-02
US61/409,297 2010-11-02
PCT/US2011/058945 WO2012071145A1 (en) 2010-11-02 2011-11-02 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Publications (3)

Publication Number Publication Date
JP2014502347A JP2014502347A (ja) 2014-01-30
JP2014502347A5 JP2014502347A5 (enExample) 2014-11-27
JP5859557B2 true JP5859557B2 (ja) 2016-02-10

Family

ID=46146161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537784A Active JP5859557B2 (ja) 2010-11-02 2011-11-02 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法

Country Status (8)

Country Link
US (2) US9182396B2 (enExample)
EP (2) EP3095876A1 (enExample)
JP (1) JP5859557B2 (enExample)
AU (2) AU2011332241B2 (enExample)
CA (1) CA2816423A1 (enExample)
ES (1) ES2564290T3 (enExample)
MX (1) MX340094B (enExample)
WO (1) WO2012071145A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
US8865164B2 (en) * 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
ES2695000T3 (es) * 2013-06-10 2018-12-28 Asahi Kasei Kabushiki Kaisha Kit de diagnóstico inmunocromatográfico
CN106461661A (zh) 2014-05-02 2017-02-22 Uab研究基金会 用于诊断和治疗脑膜炎的方法及组合物
US11029318B2 (en) * 2015-08-28 2021-06-08 Kypha, Inc. Methods for predicting and treating patients with increased risk of adverse pregnancy outcome
KR102141591B1 (ko) * 2016-05-13 2020-09-14 광주과학기술원 진단용 키트
US11913951B2 (en) * 2018-03-26 2024-02-27 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement C3 convertase
EP3581934A1 (en) * 2018-06-14 2019-12-18 Otto-von-Guericke-Universität Magdeburg Complement factors for diagnosis of low-grade infections in a human subject
WO2021222169A1 (en) * 2020-04-27 2021-11-04 Zinselmeyer Bernd H Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
EP4286850A4 (en) * 2021-01-26 2024-11-27 Sekisui Medical Co., Ltd. IMMUNOLOGICAL ASSAY PROCEDURE
EP4334719A4 (en) * 2021-05-07 2025-04-16 Kypha, Inc. TARGET MEASUREMENT
WO2023192436A1 (en) * 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
JPS595958B2 (ja) 1975-12-30 1984-02-08 トウキヨウケイソウ カブシキガイシヤ 変量測定・伝送装置
EP0097440B1 (en) * 1982-06-14 1986-09-24 The Upjohn Company Method and kit for removing and assaying complement system fragments
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
SE452067B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Reagens for och sett vid immunkemisk bestemning av c3a
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
WO2003062824A1 (en) * 2002-01-23 2003-07-31 Boditech Inc. Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor
WO2004093636A2 (en) * 2003-04-17 2004-11-04 Rauno Joks PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
US20070224703A1 (en) * 2003-09-29 2007-09-27 Fariba Nayeri Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids
US20050255533A1 (en) * 2004-02-10 2005-11-17 Brendan Bioscience, Llc Comprehensive food allergy test
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method
WO2006124888A2 (en) * 2005-05-16 2006-11-23 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
US7910381B2 (en) 2005-10-13 2011-03-22 BioAssay Works Immuno gold lateral flow assay
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
EP2313527A4 (en) * 2008-07-15 2012-11-21 Rapid Pathogen Screening Inc Lateral flow NUCLEIC DETECTOR
EP2384367A4 (en) * 2008-12-30 2013-07-10 Janssen Biotech Inc SERUM MARKERS TO PREDICT THE CLINICAL RESPONSE TO ANTI-TNF ANTIBODIES IN PATIENTS WITH MORBUS BECHTEREW
US9291622B2 (en) * 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Also Published As

Publication number Publication date
US20150346211A1 (en) 2015-12-03
US9182396B2 (en) 2015-11-10
AU2016200772B2 (en) 2018-02-01
EP3095876A1 (en) 2016-11-23
EP2635702B1 (en) 2016-02-03
AU2011332241A1 (en) 2013-05-23
MX2013004960A (es) 2013-12-16
JP2014502347A (ja) 2014-01-30
AU2011332241A2 (en) 2013-06-13
AU2016200772A1 (en) 2016-02-25
AU2011332241B2 (en) 2015-11-26
EP2635702A4 (en) 2014-04-02
WO2012071145A1 (en) 2012-05-31
US20120141457A1 (en) 2012-06-07
US9939446B2 (en) 2018-04-10
ES2564290T3 (es) 2016-03-21
MX340094B (es) 2016-06-27
EP2635702A1 (en) 2013-09-11
CA2816423A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
EP2635702B1 (en) Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
US9164088B2 (en) Detecting complement activation
WO2014068018A1 (en) Methods of prognosis and diagnosis of sepsis
JP2017207521A (ja) 補体活性化の検出
CN115190973B (zh) 基于可溶性clec-2与血小板数的血小板活化测定方法
US10830774B2 (en) Methods and compositions for diagnosis and treatment of meningitis
JP7454945B2 (ja) 血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
US20170315130A1 (en) Early prediction of preeclampsia
HK1208267B (en) Detecting complement activation
HK1234826A1 (en) Methods and compositions for diagnosis and treatment of meningitis
HK1234826B (en) Methods and compositions for diagnosis and treatment of meningitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151216

R150 Certificate of patent or registration of utility model

Ref document number: 5859557

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250